vs
芝商所（CME）与奎斯特诊断（DGX）财务数据对比。点击上方公司名可切换其他公司
奎斯特诊断的季度营收约是芝商所的1.5倍（$2.9B vs $1.9B），奎斯特诊断净利率更高（9.7% vs 0.1%，领先9.6%），芝商所同比增速更快（14.5% vs 9.2%），过去两年芝商所的营收复合增速更高（10.8% vs 9.9%）
芝商所是总部位于美国伊利诺伊州芝加哥的金融服务企业，为全球规模最大的金融衍生品交易所运营商，旗下拥有芝加哥商品交易所、芝加哥期货交易所、纽约商业交易所、纽约商品交易所等交易平台，覆盖农产品、货币、能源等品类交易，同时持有标普道琼斯指数27%的股权。
奎斯特诊断是美国头部临床检验服务商，位列《财富》500强，业务覆盖美国、波多黎各、墨西哥及巴西，同时与全球范围内多家医院、诊所保持长期协作关系，为不同地区的客户提供专业临床检验相关服务。
CME vs DGX — 直观对比
营收规模更大
DGX
是对方的1.5倍
$1.9B
营收增速更快
CME
高出5.3%
9.2%
净利率更高
DGX
高出9.6%
0.1%
两年增速更快
CME
近两年复合增速
9.9%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.9B | $2.9B |
| 净利润 | $1.2M | $281.0M |
| 毛利率 | — | — |
| 营业利润率 | 0.1% | 15.4% |
| 净利率 | 0.1% | 9.7% |
| 营收同比 | 14.5% | 9.2% |
| 净利润同比 | 20.7% | 12.0% |
| 每股收益（稀释后） | — | $2.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CMEDGX
| Q1 26 | $1.9B | $2.9B | ||
| Q4 25 | $1.6B | $2.8B | ||
| Q3 25 | $1.5B | $2.8B | ||
| Q2 25 | $1.7B | $2.8B | ||
| Q1 25 | $1.6B | $2.7B | ||
| Q4 24 | $1.5B | $2.6B | ||
| Q3 24 | $1.6B | $2.5B | ||
| Q2 24 | $1.5B | $2.4B |
净利润CMEDGX
| Q1 26 | $1.2M | $281.0M | ||
| Q4 25 | $1.2B | $245.0M | ||
| Q3 25 | $908.0M | $245.0M | ||
| Q2 25 | $1.0B | $282.0M | ||
| Q1 25 | $956.2M | $220.0M | ||
| Q4 24 | $874.6M | $222.0M | ||
| Q3 24 | $912.8M | $226.0M | ||
| Q2 24 | $883.2M | $229.0M |
毛利率CMEDGX
| Q1 26 | — | — | ||
| Q4 25 | — | 32.4% | ||
| Q3 25 | — | 33.7% | ||
| Q2 25 | — | 34.2% | ||
| Q1 25 | — | 32.5% | ||
| Q4 24 | — | 32.7% | ||
| Q3 24 | — | 32.6% | ||
| Q2 24 | — | 33.5% |
营业利润率CMEDGX
| Q1 26 | 0.1% | 15.4% | ||
| Q4 25 | 61.8% | 13.8% | ||
| Q3 25 | 63.3% | 13.7% | ||
| Q2 25 | 66.7% | 15.9% | ||
| Q1 25 | 67.5% | 13.0% | ||
| Q4 24 | 62.1% | 13.8% | ||
| Q3 24 | 64.6% | 13.3% | ||
| Q2 24 | 65.3% | 14.8% |
净利率CMEDGX
| Q1 26 | 0.1% | 9.7% | ||
| Q4 25 | 71.7% | 8.7% | ||
| Q3 25 | 59.1% | 8.7% | ||
| Q2 25 | 60.6% | 10.2% | ||
| Q1 25 | 58.2% | 8.3% | ||
| Q4 24 | 57.3% | 8.5% | ||
| Q3 24 | 57.6% | 9.1% | ||
| Q2 24 | 57.6% | 9.6% |
每股收益（稀释后）CMEDGX
| Q1 26 | — | $2.24 | ||
| Q4 25 | $3.24 | $2.18 | ||
| Q3 25 | $2.49 | $2.16 | ||
| Q2 25 | $2.81 | $2.47 | ||
| Q1 25 | $2.62 | $1.94 | ||
| Q4 24 | $2.40 | $1.95 | ||
| Q3 24 | $2.50 | $1.99 | ||
| Q2 24 | $2.42 | $2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.4B | $393.0M |
| 总债务越低越好 | $3.4B | $5.7B |
| 股东权益账面价值 | — | $7.7B |
| 总资产 | $202.0B | $16.7B |
| 负债/权益比越低杠杆越低 | — | 0.74× |
8季度趋势，按日历期对齐
现金及短期投资CMEDGX
| Q1 26 | $2.4B | $393.0M | ||
| Q4 25 | $4.5B | $420.0M | ||
| Q3 25 | $2.6B | $432.0M | ||
| Q2 25 | $2.1B | $319.0M | ||
| Q1 25 | $1.5B | $188.0M | ||
| Q4 24 | $3.0B | $549.0M | ||
| Q3 24 | $2.4B | $764.0M | ||
| Q2 24 | $1.9B | $271.0M |
总债务CMEDGX
| Q1 26 | $3.4B | $5.7B | ||
| Q4 25 | — | $5.2B | ||
| Q3 25 | — | $5.2B | ||
| Q2 25 | — | $5.2B | ||
| Q1 25 | — | $5.9B | ||
| Q4 24 | — | $5.6B | ||
| Q3 24 | — | $5.6B | ||
| Q2 24 | — | $3.8B |
股东权益CMEDGX
| Q1 26 | — | $7.7B | ||
| Q4 25 | $28.7B | $7.2B | ||
| Q3 25 | $28.2B | $7.3B | ||
| Q2 25 | $27.7B | $7.2B | ||
| Q1 25 | $27.0B | $6.9B | ||
| Q4 24 | $26.5B | $6.8B | ||
| Q3 24 | $28.2B | $6.8B | ||
| Q2 24 | $27.6B | $6.6B |
总资产CMEDGX
| Q1 26 | $202.0B | $16.7B | ||
| Q4 25 | $198.4B | $16.2B | ||
| Q3 25 | $187.1B | $16.2B | ||
| Q2 25 | $179.9B | $16.0B | ||
| Q1 25 | $157.8B | $15.8B | ||
| Q4 24 | $137.4B | $16.2B | ||
| Q3 24 | $137.8B | $16.1B | ||
| Q2 24 | $123.4B | $13.9B |
负债/权益比CMEDGX
| Q1 26 | — | 0.74× | ||
| Q4 25 | — | 0.72× | ||
| Q3 25 | — | 0.71× | ||
| Q2 25 | — | 0.72× | ||
| Q1 25 | — | 0.85× | ||
| Q4 24 | — | 0.83× | ||
| Q3 24 | — | 0.83× | ||
| Q2 24 | — | 0.58× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $278.0M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | 3.9% |
| 现金转化率经营现金流/净利润 | — | 0.99× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CMEDGX
| Q1 26 | — | $278.0M | ||
| Q4 25 | $1.1B | $465.0M | ||
| Q3 25 | $968.1M | $563.0M | ||
| Q2 25 | $1.1B | $544.0M | ||
| Q1 25 | $1.1B | $314.0M | ||
| Q4 24 | $1.0B | $464.0M | ||
| Q3 24 | $1.0B | $356.0M | ||
| Q2 24 | $776.9M | $360.0M |
自由现金流CMEDGX
| Q1 26 | — | — | ||
| Q4 25 | $1.1B | $307.0M | ||
| Q3 25 | $949.7M | $419.0M | ||
| Q2 25 | $1.0B | $436.0M | ||
| Q1 25 | $1.1B | $197.0M | ||
| Q4 24 | $991.7M | $341.0M | ||
| Q3 24 | $973.2M | $250.0M | ||
| Q2 24 | $758.7M | $268.0M |
自由现金流率CMEDGX
| Q1 26 | — | — | ||
| Q4 25 | 66.8% | 10.9% | ||
| Q3 25 | 61.8% | 14.9% | ||
| Q2 25 | 61.5% | 15.8% | ||
| Q1 25 | 67.1% | 7.4% | ||
| Q4 24 | 65.0% | 13.0% | ||
| Q3 24 | 61.4% | 10.0% | ||
| Q2 24 | 49.5% | 11.2% |
资本支出强度CMEDGX
| Q1 26 | — | 3.9% | ||
| Q4 25 | 2.0% | 5.6% | ||
| Q3 25 | 1.2% | 5.1% | ||
| Q2 25 | 1.1% | 3.9% | ||
| Q1 25 | 0.9% | 4.4% | ||
| Q4 24 | 1.7% | 4.7% | ||
| Q3 24 | 1.9% | 4.3% | ||
| Q2 24 | 1.2% | 3.8% |
现金转化率CMEDGX
| Q1 26 | — | 0.99× | ||
| Q4 25 | 0.96× | 1.90× | ||
| Q3 25 | 1.07× | 2.30× | ||
| Q2 25 | 1.03× | 1.93× | ||
| Q1 25 | 1.17× | 1.43× | ||
| Q4 24 | 1.16× | 2.09× | ||
| Q3 24 | 1.10× | 1.58× | ||
| Q2 24 | 0.88× | 1.57× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
